{"id":"https://openalex.org/W1885924420","doi":null,"title":"Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.","display_name":"Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.","publication_year":1990,"publication_date":"1990-07-01","ids":{"openalex":"https://openalex.org/W1885924420","mag":"1885924420","pmid":"https://pubmed.ncbi.nlm.nih.gov/2162251"},"language":"en","primary_location":{"id":"pmid:2162251","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2162251","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Comparative Study"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5114015935","display_name":"D. H. M. Lau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D H Lau","raw_affiliation_strings":["Department of Medicine, Stanford University School of Medicine, California 94305-5306"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Stanford University School of Medicine, California 94305-5306","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081386446","display_name":"Kevin L. Ross","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K L Ross","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5019649110","display_name":"Branimir Ivan Sikic","orcid":"https://orcid.org/0000-0001-6814-2070","observed_orcids":["https://orcid.org/0000-0001-6814-2070"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B I Sikic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3588,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.49611887,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"50","issue":"13","first_page":"4056","last_page":"60"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.698199987411499,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.698199987411499,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.11410000175237656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.05820000171661377,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5849999785423279},{"id":"https://openalex.org/keywords/ovarian-carcinoma","display_name":"ovarian carcinoma","score":0.8130000233650208},{"id":"https://openalex.org/keywords/dna-cross-linking","display_name":"DNA cross-linking","score":0.9440000057220459},{"id":"https://openalex.org/keywords/dna-strand-breaks","display_name":"DNA strand breaks","score":0.996999979019165},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.9290000200271606},{"id":"https://openalex.org/keywords/topoisomerase-ii","display_name":"topoisomerase II","score":0.9710000157356262},{"id":"https://openalex.org/keywords/alkaline-elution","display_name":"alkaline elution","score":0.8399999737739563}],"concepts":[{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.6932216882705688},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.6429179906845093},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.6278426647186279},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5710423588752747},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.5484505295753479},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.528132975101471},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.4411592185497284},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.41234761476516724},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37608033418655396},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3272213935852051},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3030018210411072},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2688325047492981},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2218920886516571},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1817878782749176}],"mesh":[{"descriptor_ui":"D003432","descriptor_name":"Cross-Linking Reagents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004249","descriptor_name":"DNA Damage","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004250","descriptor_name":"DNA Topoisomerases, Type II","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D004273","descriptor_name":"DNA, Neoplasm","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:2162251","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2162251","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Comparative Study"},{"id":"mag:1885924420","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2162251","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4603758533","display_name":"Pharmacogenomics of ADRs: Calcineurin Inhibitor Toxicity","funder_award_id":"T32GM007065","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"},{"id":"https://openalex.org/G6919139106","display_name":"CYANO-MORPHOLINO ANTHRACYCLINES","funder_award_id":"R01CA042417","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337354","display_name":"National Institute of General Medical Sciences","ror":"https://ror.org/04q48ey07"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1505131392","https://openalex.org/W2098105528","https://openalex.org/W2041006192","https://openalex.org/W2110699486","https://openalex.org/W2095263475","https://openalex.org/W2090090086","https://openalex.org/W2015524653","https://openalex.org/W2151517113","https://openalex.org/W2168859428","https://openalex.org/W1986496200"],"abstract_inverted_index":{"The":[0,36,150,236],"cyanomorpholino":[1],"analog":[2],"of":[3,29,73,123,128,147,182,186,196,208,259,268,321],"doxorubicin":[4],"(MRA-CN)":[5],"is":[6,12,304],"a":[7,229,319],"potent":[8],"cytotoxic":[9],"agent":[10],"which":[11,163,226,316],"known":[13],"to":[14,33,44,52,88,119,125,144,179,191,246,289,298],"cross-link":[15,187],"DNA.":[16],"A":[17],"human":[18],"ovarian":[19],"carcinoma":[20],"cell":[21,61,115,140,336],"line,":[22],"ES-2,":[23],"was":[24,41,117,244],"grown":[25],"in":[26,50,56,80,97,110,137,201,211,217,232,240,251,287,300,323],"increasing":[27],"concentrations":[28,83],"MRA-CN":[30,53,81,192,292,299],"from":[31],"0.1":[32],"0.5":[34],"nM.":[35,90],"resultant":[37],"resistant":[38,43,60,332],"subline,":[39],"ES-2R,":[40],"4-fold":[42,247],"MRA-CN.":[45,129,180],"DNA":[46,66,131,170,198,233,290,294,309,313,324,328],"damage":[47],"and":[48,59,311,333],"repair":[49,188,325],"response":[51],"were":[54,68,95,134,221],"compared":[55,102],"the":[57,74,98,104,113,138,148,160,166,174,183,197,202,206,218,241,252,260,266,301,331,334],"parental":[58],"lines":[62,116,141],"using":[63],"alkaline":[64],"elution.":[65],"cross-links":[67,94,111,199,216],"detectable":[69],"after":[70,142,177,189,223],"3-h":[71],"incubation":[72],"cells":[75,100,152,176,204,220,243,262,303],"at":[76,82],"37":[77],"degrees":[78],"C":[79],"greater":[84],"than":[85,249],"or":[86],"equal":[87],"1.0":[89],"Paradoxically,":[91],"2-fold":[92],"more":[93,307],"detected":[96,136],"ES-2R":[99,161,175,203,253,302],"as":[101,156,159],"with":[103,121,173,228,306],"ES-2":[105,151,219,242],"cells.":[106,254],"This":[107],"paradoxical":[108,167],"difference":[109],"between":[112,330],"2":[114,139],"observed":[118,172],"increase":[120,231,265],"time":[122,184],"exposure":[124,143,178,190],"2.5":[126,145],"nM":[127,146],"Non-protein-associated":[130],"strand":[132,234,270,295,314],"breaks":[133,158,271],"also":[135],"drug.":[149],"consistently":[153],"showed":[154],"twice":[155],"many":[157],"cells,":[162],"could":[164],"explain":[165],"higher":[168,248],"apparent":[169,269,308],"cross-linking":[171,310],"Studies":[181],"course":[185],"revealed":[193],"that":[194,250,276],"75%":[195],"disappeared":[200],"by":[205,273],"end":[207],"8":[209],"h":[210],"drug-free":[212],"medium.":[213],"In":[214],"contrast,":[215],"undetectable":[222],"4":[224],"h,":[225],"coincided":[227],"progressive":[230],"breaks.":[235],"topoisomerase":[237,277],"II":[238,278],"level":[239],"2-":[245],"However,":[255],"proteinase":[256],"K":[257],"treatment":[258],"lysed":[261],"did":[263],"not":[264,280],"number":[267],"produced":[272],"MRA-CN,":[274],"suggesting":[275],"may":[279,317],"be":[281,318],"involved.":[282],"These":[283],"findings":[284],"indicate":[285],"that,":[286],"addition":[288],"cross-linking,":[291],"causes":[293],"breakage.":[296],"Resistance":[297],"associated":[305],"less":[312],"breakage,":[315],"consequence":[320],"differences":[322],"and/or":[326],"nonspecific":[327],"degradation":[329],"sensitive":[335],"lines.":[337]},"counts_by_year":[{"year":2023,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}